News Digest / Ticker: TELO

Ticker: TELO

09:31am, Thursday, Aug 28, 2025

Telomir (TELO) Pops 38% After Telomir‑1 Hits UTX; Avoids GCN5L2 Toxicity Signal

Telomir Pharmaceuticals (TELO) +38% after Telomir‑1 preclinical data showed potent UTX inhibition and broader epigenetic activity, reversed tumor methylation and spared GCN5L2 - promising but in vivo/clinical proof still needed.